Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0007097 (
carcinoma
)
152,788
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An epidermal cell model in which initiated, benign tumor-producing and
carcinoma
stages were derived from a cloned parental cell strain was used to examine
p53
expression during multistage epithelial carcinogenesis. Increased steady-state levels of
p53
RNA were detected in squamous cell carcinomas compared to papilloma and normal epidermal cells. Nontumorigenic initiated cell precursors of the carcinomas exhibited normal
p53
expression, localizing altered
p53
regulation to the malignant conversion stage. Immunoprecipitation and Western immunoblot analyses demonstrated elevated levels of
p53 protein
in the moderately differentiated
carcinoma
compared to normal cells, and negligible levels of
p53
in the poorly differentiated
carcinoma
cells. Sequence analysis of
p53
complementary DNA from normal and
carcinoma
cells revealed no mutations in the coding or 5'- and 3'-untranslated regions, suggesting a novel mechanism of
p53
inactivation.
...
PMID:Altered expression of wild-type p53 tumor suppressor gene during murine epithelial cell transformation. 137 Jun 52
Production of cell-adhesion proteins was examined in 10 cell lines and 5 cultured human cancer cells at an early passage. Two-thirds of the tested cells produced and secreted into their culture medium variable amounts of material active in promoting cell attachment. One of the rectal
carcinoma
cell lines, CaR-I, grew well in serum-free medium and secreted a large amount of the active principle. The active principles produced by CaR-I cells were characterized after partial purification, and were found to be fibronectin and its fragments. The presence of fibronectin and its fragments was proved by the following facts: (1) reactivity to the monoclonal antibodies which recognize different epitopes of fibronectin, and (2) reactivity to RGD peptide which is the attachment sequence of fibronectin. In addition to fibronectin and its fragments, CaR-I cells were also shown to produce a 53-kDa attachment factor. Unexpectedly, the protein was proved to be most probably the
p53
suppressor gene product.
...
PMID:Secretion of cell-adhesion-promoting factors, fibronectin, fibronectin fragments and a 53-kDa protein, by human rectal adenocarcinoma cells. 138 37
Preinvasive lesions of squamous cell carcinoma are well defined morphologically and provide a model for multistage carcinogenesis. Since alterations in the
p53 tumor suppressor
gene occur frequently in invasive esophageal squamous cell carcinoma, we examined a set of preinvasive lesions to investigate the timing of
p53
mutation. Surgically resected tissues from nine patients with esophageal squamous cell carcinoma contained precursor lesions which had not yet invaded normal tissues. Immunohistochemistry showed high levels of
p53 protein
in both preinvasive lesions and invasive carcinomas in six cases; sequence analysis of all invasive tumors identified
p53
missense mutations in two cases. Preinvasive lesions from both tumors with mutations plus one wild-type tumor were microdissected and sequenced. In one patient there were different mutations in the invasive
carcinoma
(codon 282, CGGarg > TGGtrp) and a preinvasive lesion (codon 272, GTGval > T/GTGleu/val). In a second case, an invasive
carcinoma
had a mutation in codon 175 (CGCarg > CAChis), and adjacent preinvasive lesions contained a wild-type sequence. A
carcinoma
and preinvasive lesion from the third case contained high levels of protein and a wild-type DNA sequence. Therefore,
p53
mutation may precede invasion in esophageal carcinogenesis, and multifocal esophageal neoplasms may arise from independent clones of transformed cells. The timing of
p53 protein
accumulation is favorable for an intermediate biomarker in multistage esophageal carcinogenesis.
...
PMID:p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. 139 36
In normal cells,
p53 protein
is virtually undetectable by immunohistochemical methods. Mutation of
p53
gene results in overexpression of the protein and thus levels of
p53
detectable by immunohistochemistry may indicate expression of the mutant form of
p53
. Esophageal cancer (EC) samples obtained from patients who had undergone surgery were assayed for expression in
p53 protein
. Among 18 primary EC and their adjacent tissues, 7 cases of EC and 5 adjacent tissues overexpression of
p53 protein
was detected immunohistochemically. In cases with overexpression of the
p53
in the adjacent tissues was detected 4 were also positive in the carcinomas. These results suggest that overexpression of
p53 protein
is a common molecular event in EC and may occur in the early stage of esophageal tumorigenesis. In addition, we found over expression of the
p53 protein
in the human fetal esophageal
carcinoma
induced by NMBzA, indicating that
p53
gene mutation (s) might have occurred. The results provide further evidence that N-nitrosamine is a causative agent of human esophageal cancer.
...
PMID:[Overexpression of p53 protein in human spontaneous esophageal carcinoma and fetal esophageal carcinoma induced by N-methyl-N-benzylnitrosamine (NMBzA)]. 139 69
Wild-type and mutant human
p53
genes were transfected into the nasopharyngeal
carcinoma
(NPC) cell line CNE-3. Tumorigenicity in nude mice showed that the tumor resulting from the cells transfected with the wild-type
p53
gene grew more slowly and was smaller than that from the cells transfected with mutant p53 gene and that from control CNE-3 cells. In contrast, the tumor from the cells transfected with the mutant p53 gene grew faster than that produced by cells transfected with the wild-type
p53
gene and that produced by control CNE-3 cells. The results demonstrate that the wild-type
p53
gene could inhibit the NPC cell growth in nude mice and the mutant p53 gene could enhance the NPC cell growth in nude mice. The
p53
gene may also play an important role in the pathogenesis of NPC.
...
PMID:Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene. 140 May 65
The RB and
p53
tumour suppressor genes encode nuclear proteins that exert an inhibitive effect on cell growth. A large variety of human tumour types manifest loss or mutation of the RB or
p53
genes, and
p53
mutation is the commonest genetic alteration found in tumour cells. In addition, the RB and
p53
proteins may be inactivated by complex formation with viral oncoproteins--for instance, in the case of cervical
carcinoma
carrying human papilloma virus. In vivo introduction of an intact RB or
p53
gene into malignant cells lacking the respective gene results in suppression of the neoplastic phenotype and thus of tumourigenicity,
p53
being the more potent of the two in this respect. Further elucidation of tumour suppressor genes may well result in future improvement in the diagnosis and treatment of cancer.
...
PMID:[Tumor suppressor genes: mutations in RB and p53 genes are significant carcinogenic factors]. 140 28
The expression of the
p53
gene product was investigated immunocytochemically in a retrospective series of 164 formalin-fixed paraffin-embedded invasive breast carcinomas with pathologically proven negative lymph nodes. Overall, 78 tumors (48%) showed a variable degree of
p53
immunoreactivity. Among these, 38 cases were low expressors (1-10%
p53
immunoreactive tumor cells), 21 moderate expressors (10-50% immunoreactive cells) and 19 high expressors (> 50% immunoreactive cells). Abnormal
p53
expression correlated significantly with tumor size, histological and nuclear grade, DNA ploidy, mitotic rate and proliferation index, and with the lack of estrogen receptors. Disease-free and adjusted survival analysis of the 124 node-negative patients with long term (more than 10 years) follow-up, however, did not reveal an independent prognostic role for
p53
expression. These data suggest that the evaluation of
p53
immunoreactivity may only play a role in a multiparametric prognostic assessment of node-negative breast
carcinoma
.
...
PMID:Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. 141 93
The
p53
expression in various skin tumors was immunohistologically evaluated using two mouse monoclonal anti-
p53
antibodies, PAb421 and PAb1801. The
p53
expression was not detected in the normal epidermal cells. Nuclear staining suggested that the
p53
expression was observed in 10 of 26 squamous cell carcinomas (SCCs) from 24 patients, in one undifferentiated
carcinoma
, one proliferating trichilemmal cyst, one malignant proliferating trichilemmal tumor and in one metastatic
carcinoma
of breast cancer. None off four cases of Bowen's disease (SCC in situ) showed nuclear staining. In the SCCs, five of 20 primary lesions, three of four recurrent lesions and both of two metastatic lesions had positive nuclei. There was one case of SCC in which a primary lesion was negative but a recurrent lesion was positive. Thus,
p53
expression was more frequently observed in SCCs at more clinically advanced stages. This may suggest that
p53
has some relevance to progression of SCC. Nuclear staining was not detected in any of the following cases: two cases of seborrheic keratosis, one eccrine poroma, one keratoacanthoma, 11 basal cell epitheliomas, two mammary Paget's disease, three genital Paget's disease, one sebaceous
carcinoma
, four malignant melanomas, six lymphomas, two leukemia cutis and two angiosarcomas.
...
PMID:Immunohistological analysis of P53 expression in human skin tumors. 830 55
p53
point mutations in primary gastric carcinomas were analyzed by performing cDNA deoxynucleotide sequencing of the gene. Out of 16, 9 (56.3%) primary gastric
carcinoma
cases, including early cancer, showed one or more
p53
point mutations in their open-reading frame, and 4 out of 9 cases had a
p53
point mutation within highly conserved domains. The characteristics of the
p53
mutation spectrum observed in primary tumors were (a) frequent mutation at an A:T pair (50%, 7 out of 14 mutations), (b) high transversion incidence (29%, 4 out of 14 mutations), (c) no transition at CpG, and (d) no G:C to T:A transversion. Our results suggest that
p53
mutation is a common event in gastric
carcinoma
occurring from the early stage of progression with its specific mutation spectrum.
...
PMID:p53 point mutations in primary human gastric carcinomas. 142 28
There are many reports of cell lines being established from human oral squamous-cell carcinomas but apparently none of cell lines from dysplastic or "pre-malignant" oral mucosa. We describe here the isolation and characterization of a cell line, DOK (dysplastic oral keratinocyte), from a piece of dorsal tongue showing epithelial dysplasia. The tissue was obtained from a 57-year-old man who was a heavy smoker prior to the appearance of a white patch on his tongue. Eleven years later a squamous-cell
carcinoma
developed at the site and was excised. Subsequently the remaining dysplasia was removed, and it was from a piece of this that the primary cell cultures which eventually gave rise to DOK were initiated. The DOK line has been single-cell cloned and is apparently immortal. It grows in the absence of 3T3 feeder cells, is anchorage-dependent for growth and is non-tumorigenic in nude mice. The keratin profile of the cells shows a striking similarity to that of the original tongue dysplasia. The karyotype of DOK is aneuploid and complex. By PCR and oligonucleotide hybridization on dot blots, codons 12, 13 and 61 of Ha-ras, Ki-ras and N-ras in DNA extracted from DOK cells were shown to be normal. Immunohistochemistry showed no abnormal, i.e., elevated expression of the onco-suppressor
protein p53
. Because of its origin and partially transformed phenotype, DOK presents an opportunity to study whether specific carcinogens associated with tobacco and areca nut can cause malignant transformation of oral keratinocytes in vitro.
...
PMID:DOK, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. 145 32
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>